TY - JOUR
T1 - Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to β-lactam antibiotics
AU - Dahesh, Samira
AU - Hensler, Mary E.
AU - van Sorge, Nina M.
AU - Gertz Jr., Robert E.
AU - Schrag, Stephanie
AU - Nizet, Victor
AU - Beall, Bernard W.
PY - 2008/8
Y1 - 2008/8
N2 - Beta-lactam antibiotics (BLAs) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x. Copyright © 2008, American Society for Microbiology. All Rights Reserved.
AB - Beta-lactam antibiotics (BLAs) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared a pbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-type pbp2x. Copyright © 2008, American Society for Microbiology. All Rights Reserved.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=48749093934&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/18541727
U2 - https://doi.org/10.1128/AAC.00461-08
DO - https://doi.org/10.1128/AAC.00461-08
M3 - Article
C2 - 18541727
SN - 0066-4804
VL - 52
SP - 2915
EP - 2918
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 8
ER -